Pfizer Goodwill and Intangible Assets 2012-2026 | PFE
Pfizer goodwill and intangible assets from 2012 to 2026. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
- Pfizer goodwill and intangible assets for the quarter ending March 31, 2026 were $120.425B, a 6.32% decline year-over-year.
- Pfizer goodwill and intangible assets for 2024 were $123.938B, a 6.59% decline from 2023.
- Pfizer goodwill and intangible assets for 2023 were $132.683B, a 40.04% increase from 2022.
- Pfizer goodwill and intangible assets for 2022 were $94.745B, a 27.42% increase from 2021.
|
Pfizer Annual Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2024 | $123,938 |
| 2023 | $132,683 |
| 2022 | $94,745 |
| 2021 | $74,354 |
| 2020 | $77,893 |
| 2019 | $82,138 |
| 2018 | $88,622 |
| 2017 | $104,693 |
| 2016 | $107,097 |
| 2015 | $88,598 |
| 2014 | $77,235 |
| 2013 | $81,904 |
| 2012 | $88,807 |
| 2011 | $95,753 |
|
Pfizer Quarterly Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2025-09-30 | $120,425 |
| 2025-06-30 | $121,699 |
| 2025-03-31 | $122,420 |
| 2024-12-31 | $123,938 |
| 2024-09-30 | $128,556 |
| 2024-06-30 | $129,685 |
| 2024-03-31 | $132,126 |
| 2023-12-31 | $132,683 |
| 2023-09-30 | $91,751 |
| 2023-06-30 | $92,978 |
| 2023-03-31 | $93,478 |
| 2022-12-31 | $94,745 |
| 2022-09-30 | $77,592 |
| 2022-06-30 | $78,956 |
| 2022-03-31 | $80,027 |
| 2021-12-31 | $74,354 |
| 2021-09-30 | $75,795 |
| 2021-06-30 | $77,190 |
| 2021-03-31 | $77,765 |
| 2020-12-31 | $77,893 |
| 2020-09-30 | $90,829 |
| 2020-06-30 | $91,990 |
| 2020-03-31 | $92,966 |
| 2019-12-31 | $82,138 |
| 2019-09-30 | $97,660 |
| 2019-06-30 | $86,376 |
| 2019-03-31 | $87,526 |
| 2018-12-31 | $88,622 |
| 2018-09-30 | $100,920 |
| 2018-06-30 | $102,420 |
| 2018-03-31 | $104,083 |
| 2017-12-31 | $104,693 |
| 2017-09-30 | $105,799 |
| 2017-06-30 | $106,362 |
| 2017-03-31 | $107,083 |
| 2016-12-31 | $107,097 |
| 2016-09-30 | $110,519 |
| 2016-06-30 | $93,656 |
| 2016-03-31 | $88,160 |
| 2015-12-31 | $88,598 |
| 2015-09-30 | $90,514 |
| 2015-06-30 | $74,995 |
| 2015-03-31 | $76,188 |
| 2014-12-31 | $77,235 |
| 2014-09-30 | $79,098 |
| 2014-06-30 | $80,021 |
| 2014-03-31 | $80,589 |
| 2013-12-31 | $81,904 |
| 2013-09-30 | $82,949 |
| 2013-06-30 | $84,207 |
| 2013-03-31 | $87,861 |
| 2012-12-31 | $88,807 |
| 2012-09-30 | $91,579 |
| 2012-06-30 | $92,967 |
| 2012-03-31 | $98,053 |
| 2011-12-31 | $95,753 |
| 2011-09-30 | $101,006 |
| 2011-06-30 | $102,166 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |